Malignant Lymphomas |
Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK
Correspondence: Mark S Cragg, Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. E-mail: msc{at}soton.ac.uk
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
Key words: CD20, monoclonal antibodies, lymphoma, immunotherapy.
This article has been cited by other articles:
![]() |
S. A. Beers, R. R. French, H. T. C. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection Blood, June 24, 2010; 115(25): 5191 - 5201. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Beers, M. S. Cragg, and M. J. Glennie Complement: help or hindrance? Blood, December 24, 2009; 114(27): 5567 - 5568. [Full Text] [PDF] |
||||
![]() |
M. Introna and J. Golay Complement in antibody therapy: friend or foe? Blood, December 17, 2009; 114(26): 5247 - 5248. [Full Text] [PDF] |
||||